Abstract
The pandemic caused by the SARS-CoV-2 has made new treatments a goal for the scientific community. One of these treatments is Ivermectin. Here we discuss the hypothesis of dysbiosis caused by the use of Ivermectin and the possible impacts on neuroinflammatory diseases after the end of the pandemic.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Autoimmune Diseases of the Nervous System / epidemiology
-
Autoimmune Diseases of the Nervous System / etiology
-
COVID-19 / complications
-
COVID-19 / epidemiology*
-
COVID-19 / virology*
-
COVID-19 Drug Treatment
-
Disease Susceptibility
-
Dysbiosis / epidemiology*
-
Dysbiosis / etiology
-
Humans
-
Ivermectin / adverse effects
-
Ivermectin / therapeutic use
-
SARS-CoV-2* / drug effects
-
SARS-CoV-2* / immunology